You are here

Welcome to Pfizer’s news section — designed to give you access to timely and relevant information about our company. In this section you will find information and resources for journalists, including current and archived Pfizer press releases, a full company press kit, and a comprehensive collection of images and videos in our multimedia library.

Pfizer Inc. (NYSE:PFE) today announced that it will expand the company’s Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) program in 2017 to award up to $5.5 million (USD) in new competitive grants to fund research studies involving Pfizer products in both breast and hematologic cancers. This expanded program will be known as the ASPIRE Oncology/Hematology Clinical Research Awards.

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Citi 2016 Global Healthcare Conference on Thursday, December 8, 2016 at 2:10 p.m. Eastern Standard Time.

Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to 16 years of age with partial onset seizures. Results showed that adjunctive treatment with LYRICA 10 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint. Treatment with LYRICA 2.5 mg/kg/day resulted in a numerical reduction in seizure frequency, which was not statistically significant.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.